| Vol. 12.44 – 20 November, 2020 |
| |
|
|
| Scientists demonstrated potent single-agent activity of anti-CD25 antibodies optimized to deplete Treg cells, while preserving IL-2-STAT5 signaling on effector T cells and showed synergy with immune checkpoint blockade in vivo. [Nature Cancer] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers report an alternative mechanism of targeted protein degradation, in which a small molecule induced the highly specific, reversible polymerization of a target protein, followed by its sequestration into cellular foci and subsequent degradation. [Nature] |
|
|
|
| Investigators showed that isoprenoid-dependent posttranslational lipid modifications dictated effector regulatory T cell accumulation and function by intersecting with T cell receptor-induced intracellular signaling. [Cell Metabolism] |
|
|
|
| The authors found that the source of transforming growth factor-β-supporting resident memory T cells was autocrine. [Immunity] |
|
|
|
| Researchers showed that pro-inflammatory M1-like macrophages, but not naive or M2 macrophages, accumulate in metabolic tissues, including visceral white adipose tissue and liver, during ageing and acute responses to inflammation. [Nature Metabolism] |
|
|
|
| Scientists showed that an increase in CD38 in white adipose tissue and the liver during aging was mediated by accumulation of CD38+ immune cells. Inflammation increased CD38 and decreased NAD+. [Nature Metabolism] |
|
|
|
| In vitro, epigenome‐editing of carbon tetrachloride (CCL2) enhancer and promoter regions by CRISPR‐dCas9‐KRAB technology repressed TNFα‐induced CCL2 transcription via H3K9 tri‐methylation. [Hepatology] |
|
|
|
| Scientists demonstrated that cell-intrinsic IL-33 promoted mouse dendritic cells to express the pore-forming protein perforin-2, which may function as a conduit on the plasma membrane facilitating IL-33 export. [Science Immunology] |
|
|
|
| The authors found that the reparative macrophage transition was dictated by B-cell adapter for PI3K (BCAP). Mice harboring a macrophage-specific deletion of BCAP fail to recover from and succumb to dextran sulfate sodium-induced colitis due to prolonged intestinal inflammation and impaired tissue repair. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Recruitment of myeloid-derived suppressor cells into the tumor microenvironment contributes to cancer immune evasion. Scientists compared the growth and metastasis of melanoma and breast cancer xenografts in mice exhibiting or not exhibiting targeted deletion of Cxcr2 in myeloid cells. [Cancer Immunology Research] |
|
|
|
| By combining longitudinal manganese-enhanced magnetic resonance imaging and immune profiling of a sporadic mouse model of sonic hedgehog subgroup of medulloblastoma, researchers found the density of tumor-associated macrophages/microglia was higher in the ~50% of tumors that progress to lethal disease. [Oncogene] |
|
|
|
| Investigators showed that platelet-derived programmed cell death protein-1 (PD-L1) regulated the growth of PD-L1 negative tumors and that interference with platelet binding to PD-L1 negative cancer cells promoted T cell-induced cancer cytotoxicity. [Scientific Reports] |
|
|
|
|
| The authors focus on how metabolic alterations underlie airway macrophage phenotype and function during chronic lung diseases. [Mucosal Immunology] |
|
|
|
|
| Proteintech and HebeCell announced their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor technology for the development and commercialization of iPSC-derived natural killer cells, a promising cellular immunotherapy treatment for cancer and other diseases. [Proteintech] |
|
|
|
|
| April 9 – April 14, 2021 Washington, DC, United States |
|
|
|
|
|
| Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| University of Dundee – Dundee, Scotland, United Kingdom |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Queen’s University – Kingston, Ontario, Canada |
|
|
|
| Terasaki Research Institute – Los Angeles, California, United States |
|
|
|
|